Ligand Pharmaceuticals (LGND) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ligand Pharmaceuticals (LGND) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 59.9% versus a loss of 3.0%. Over five years, LGND leads with a +260.9% price change compared with +64.2% for PTCT. Ligand Pharmaceuticals is the larger company by market cap ($5.88 billion vs $5.22 billion), about 1.1 times the size, while PTC Therapeutics is growing revenue faster (+114.5% vs +60.4%).
On valuation, Ligand Pharmaceuticals trades at a lower forward P/E (24.7x vs 26.4x for PTC Therapeutics). Ligand Pharmaceuticals converts more of its revenue into profit, with a net margin of 46.4% versus 39.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGND | PTCT |
|---|---|---|
| Share price | $295.00 | $62.56 |
| Market cap | $5.88B | $5.22B |
| 1-day change | +0.59% | -1.06% |
| YTD return | +56.03% | -17.64% |
| 1-year return | +59.90% | -2.98% |
| 5-year return | +260.89% | +64.24% |
| P/E ratio (TTM) | 31.09 | — |
| Forward P/E | 24.69 | 26.40 |
| EPS (TTM) | $9.49 | $-0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $268.09M | $1.73B |
| Revenue growth (YoY) | +60.40% | +114.51% |
| Net income (latest FY) | $124.45M | $682.64M |
| Operating margin | 15.29% | 50.09% |
| Net margin | 46.42% | 39.44% |
| 52-week high | $326.63 | $90.87 |
| 52-week low | $175.89 | $61.23 |
| Distance from 52-week high | -9.68% | -31.15% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +16.69% | +62.71% |
| Average volume | 258.59K | 1.14M |
| Shares outstanding | 19.94M | 83.46M |
| Employees | 47 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LGND has outperformed PTCT by 62.9 percentage points over the past year.
- Ligand Pharmaceuticals is more profitable, keeping 46.4 cents of every revenue dollar as net income versus 39.4 cents for PTC Therapeutics.
- PTC Therapeutics grew revenue faster in its latest fiscal year (+114.51% vs +60.40%).
About Ligand Pharmaceuticals
LGND stock →Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
LGND vs PTCT FAQ
Which is bigger, Ligand Pharmaceuticals or PTC Therapeutics?
Ligand Pharmaceuticals (LGND) is larger, with a market capitalization of $5.88B compared with $5.22B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, LGND or PTCT?
LGND returned +59.90% over the past 12 months, compared with -2.98% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Ligand Pharmaceuticals and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.